Source: Annual Congress 2002 - Prevalence and costs of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. B. Oostenbrink, M. P. M. H. Rutten-van Molken, S. Anton, P. Koch (Rotterdam, The Netherlands; Ridgefield, United States Of America; Ingelheim, Germany). A Markov model based on COPD disease severity to analyse the results from tiotropium trials. Eur Respir J 2002; 20: Suppl. 38, 833

Member's Comments

No comment yet.

Related content which might interest you: Budesonide/formoterol is more cost-effective than salmeterol/fluticasone in severe COPD: a Markov model simulation Source: Eur Respir J 2006; 28: Suppl. 50, 738s Year: 2006 The utility of tiotropium among patients with chronic obstructive pulmonary disease (COPD): An updated meta-analysis of randomized controlled trials Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 A prediction model for exacerbations in patients with COPD generated in a Swiss multicenter COPD cohort study (TOPDOCS) Source: International Congress 2017 – Primary care management of asthma and COPD Year: 2017 Clinical features and functional parameters predict the probability of ACO in patients with asthma and COPD Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018 What is the best method for investigating the impact of tiotropium on hyperinflation in COPD? Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Prediction models for exacerbations in patients with COPD Source: Eur Respir Rev 2017; 26: 160061 Year: 2017 Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic population model for COPD Source: Annual Congress 2011 - Respiratory epidemiology: quality of life, therapy and socioeconomics Year: 2011 Assessment of variations in control of asthma over time Source: Eur Respir J 2003; 22: 298-304 Year: 2003 Comparison of multidimensional assessment systems with regard to risk prediction for exacerbations of COPD Source: Annual Congress 2011 - COPD exacerbation Year: 2011 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 Prediction models for exacerbations in different COPD patient populations: Results of five large databases Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD Year: 2016 PRM metrics predict COPD progression Source: International Congress 2018 – Imaging biomarkers and quantitative imaging Year: 2018 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations Source: ERJ Open Res, 5 (4) 00136-2019; 10.1183/23120541.00136-2019 Year: 2019 Clinical clustering of COPD patients is useful to predict future COPD exacerbations Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 How to reduce COPD exacerbations with inhaled drugs? A pooled analysis of randomized trials Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 The impact of using different symptom-based exacerbation definitions in COPD patients Source: Annual Congress 2010 - Exacerbations and COPD and rehabilitation Year: 2010 Prediction model of COPD acute exacerbation with big data by machine learning methods Source: Virtual Congress 2020 – Prediction and management of outcomes in obstructive diseases Year: 2020 Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019